Analysts are on the Bearish side about GlaxoSmithKline plc (ADR) (NYSE:GSK) this week.

June 19, 2017 - By Ellis Scott

 Analysts are on the Bearish side about GlaxoSmithKline plc (ADR) (NYSE:GSK) this week.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Among 13 analysts covering GlaxoSmithKline (NYSE:GSK), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. GlaxoSmithKline had 20 analyst reports since September 8, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, July 14 by Jefferies. On Wednesday, January 27 the stock rating was upgraded by Bryan Garnier & Cie to “Buy”. The firm has “Underperform” rating given on Wednesday, September 14 by BNP Paribas. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Neutral” rating given on Tuesday, September 15 by BNP Paribas. Bank of America upgraded the shares of GSK in report on Tuesday, September 8 to “Neutral” rating. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Overweight” rating given on Friday, September 23 by Piperjaffray. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Neutral” rating by Credit Suisse on Tuesday, October 20. On Wednesday, April 5 the stock rating was upgraded by BNP Paribas to “Neutral”. The rating was upgraded by Berenberg to “Buy” on Friday, May 26. The firm has “Buy” rating by Argus Research given on Monday, December 7. Below is a list of GlaxoSmithKline plc (ADR) (NYSE:GSK) latest ratings and price target changes.

16/06/2017 Broker: J P Morgan Chase Co Rating: Neutral Maintain
26/05/2017 Broker: Berenberg Old Rating: Hold New Rating: Buy Upgrade
26/04/2017 Broker: JP Morgan Rating: Neutral Maintain
05/04/2017 Broker: BNP Paribas Old Rating: Underperform New Rating: Neutral Upgrade

About 600 shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since June 19, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.

GlaxoSmithKline plc is a global healthcare company. The company has market cap of $106.64 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 50.17 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.